NLS Pharmaceutics (NLS Pharmaceutics) Debt-to-Equity : -0.19 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Debt-to-Equity?

NLS Pharmaceutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.63 Mil. NLS Pharmaceutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. NLS Pharmaceutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-8.83 Mil. NLS Pharmaceutics's debt to equity for the quarter that ended in Dec. 2023 was -0.18.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NLS Pharmaceutics's Debt-to-Equity or its related term are showing as below:

NLSP' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.15 Med: -0.23 Max: -0.14
Current: -0.19

During the past 7 years, the highest Debt-to-Equity Ratio of NLS Pharmaceutics was -0.14. The lowest was -1.15. And the median was -0.23.

NLSP's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs NLSP: -0.19

NLS Pharmaceutics Debt-to-Equity Historical Data

The historical data trend for NLS Pharmaceutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics Debt-to-Equity Chart

NLS Pharmaceutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.14

-0.23

-0.19

NLS Pharmaceutics Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial								-	-0.09	-	-	-0.19

Competitive Comparison of NLS Pharmaceutics's Debt-to-Equity

For the Biotechnology subindustry, NLS Pharmaceutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NLS Pharmaceutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NLS Pharmaceutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NLS Pharmaceutics's Debt-to-Equity falls into.

NLS Pharmaceutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NLS Pharmaceutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.634	+	0)	/	-8.834
	=	-0.18

NLS Pharmaceutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.634	+	0)	/	-8.834
	=	-0.18

NLS Pharmaceutics (NAS:NLSP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

NLS Pharmaceutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

The Circle 6, Zurich, CHE, 8058

Website

https://www.nlspharma.com

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.